期刊
NPJ PRECISION ONCOLOGY
卷 6, 期 1, 页码 -出版社
NATURE PORTFOLIO
DOI: 10.1038/s41698-022-00329-w
关键词
-
类别
资金
- NIH [P30CA014195, DP2AT011327, K22CA216318, T32CA009370]
- American Cancer Society [19-138-34]
- MCW Cancer Center
- Joe and Dorothy Dorsett Brown Foundation
The combination of KRAS G12C inhibitors with EGFR inhibitors has shown consistent benefits, including inhibiting both wild-type and mutant RAS.
The combination of KRAS G12C inhibitors with EGFR inhibitors has reproducibly been shown to be beneficial. Here, we identify another benefit of this combination: it effectively inhibits both wild-type and mutant RAS. We believe that targeting both mutant and wild-type RAS helps explain why this combination of inhibitors is effective.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据